拜玛林制药 (BMRN.US) 2025年第三季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
Biomarin highlights advancements in skeletal conditions treatments, notably Voxogo for hypochondroplasia, with strong financial performance and strategic initiatives including pipeline optimization and potential acquisitions to drive growth and shareholder value.
会议速览
Biomarin's Q3 2025 Conference Call: Forward-Looking Statements and Non-GAAP MetricsThe biomarin Pharmaceutical Inc third quarter 2025 conference call outlines forward-looking statements regarding the company's business prospects, financial performance, and product development. It emphasizes the use of non-GAAP financial metrics, explaining their limitations and where they can be reconciled. The call focuses on non-GAAP measures unless otherwise specified, with a reminder of the disclaimer regarding potential differences in actual results due to various factors.
Biomarin's Q3 2025 Results: Revenue Growth, Strategic Decisions, and Future OutlookBiomarin raised full-year total revenue guidance, highlighting strong top-line growth driven by enzyme therapies and skeletal conditions. The company is preparing for future expansion, discontinuing some research programs and considering the divestment of Roctavian. Financial performance reflects strategic investments, and the company anticipates robust operating cash flow, aiming for record commercial results and exploring new business development opportunities.
Biomarin's Year-to-Date Results and Future Indications for Foxo Go in Skeletal ConditionsBiomarin acknowledges global team achievements, highlights Palin Z's performance, and forecasts growth in enzyme therapies. The company anticipates breakthroughs in skeletal conditions with Foxo Go, aiming for early diagnosis and treatment in hypochondroplasia, with potential launches and new indications in 2026 and 2027.
Advancing Therapies for Skeletal Disorders: Hypochondroplasia and AchondroplasiaDiscusses the impact of hypochondroplasia, highlights spinal morphology improvements with Vao in children with achondroplasia, and outlines plans for next-generation therapy BMN 333, aiming to deliver superior efficacy in achondroplasia treatment.
2027 Guidance Reevaluation: Factors Influencing DecisionQuestion raised about the rationale behind revising the 2027 guidance, prompting an explanation on the changed scenarios and considerations over the past year.
Evaluating Portfolio Outcomes Amid Voxel Go Competition and Strategic MovesAssesses factors including Voxel Go competition, Indesign acquisition, bmn 401 pediatric launch, and Roctavian divestment options, outlining a range of lower and higher case estimates for 2027 revenue due to uncertainties.
Estimating Market Impact: Lower and Upper Bound Scenarios for Competitor LaunchesDiscusses lower and upper case estimates reflecting competitor launch scenarios, emphasizing uncertainty and maintaining consensus for Biogen in 2027.
Reevaluating Competitive Impact on Fox's Market ShareDiscusses updated views on competition's effect on Fox, reflecting observed market trends and potential scenarios, emphasizing a range of outcomes rather than a fixed estimate.
Analysis of Quarterly Sales Fluctuations and Business Development Strategy in the Face of Competitive DynamicsThe dialogue discusses the quarterly sales decline of Foxo, attributing it to timing shifts in orders and market forecasts, while reaffirming annual revenue targets. It also explores the company's business development strategy, emphasizing the focus on Vox Sogo and addressing competitive challenges, with an outlook on when growth levers might emerge to enhance the portfolio.
Company's Strategy on Pursuing Deals for Enzyme Therapies and Skeletal ConditionsA company with strong business performance in enzyme therapies and skeletal conditions is prioritizing deals, including early stage collaborations and phase 3 pre-commercial assets, to add value to stakeholders. The strategy emphasizes the company's ability to enhance the worth of assets, with a focus on generating significant cash flow and maintaining a strong balance sheet. Multiple deals are in progress, reflecting the company's commitment to business development and strategic growth.
Discussion on Sustainable Growth, Market Penetration, and Capital Allocation StrategiesThe dialogue covers strategic planning for sustainable growth in enzyme therapies, emphasizing market penetration and indication expansion while acknowledging competition uncertainties. It also discusses capital allocation priorities, with a focus on business development opportunities to drive top-line growth and enhance stock appreciation, over considerations like share buybacks.
Determining Exposure Levels and Growth Velocity Deltas for Clinical Superiority in BMN 333 vs. CompetitorsThe dialogue discusses the necessary exposure levels for BMN 333 to show clinical superiority over Voxel Go and Foxo. It highlights the minimum annualized growth velocity delta required to demonstrate superiority, aiming to drive patient switching and re-establish the standard of care amid competition.
Discussion on Phase 1 PK Study Results and Dose Ranging for New TherapyA phase 1 PK study showed three dose levels achieving at least 3x increase in AUC for free CNP levels. The team is focusing on clinically meaningful differentiation for next generation therapy, aiming for improvements beyond linear growth to health and wellness measures, with specific details to be revealed later.
2027 Financial Targets and Pipeline Updates for Biotech CompanyDiscussion on 2027 revenue guidance excluding roctavian, maintaining 40% non-GAAP operating margin targets, and updates on pipeline developments including 351's 6mg and 9mg cohorts, and hypochondroplasia trial powering, emphasizing ambitious dystrophin level goals and confidence in study design.
Cash Flow and Capital Allocation Strategy for GrowthDiscusses significant operating cash flow generation, future working capital optimization, and deploying cash as growth capital, emphasizing the tie between cash flow and revenue scenarios.
Market Trends, Competitive Risks, and DMD Program GoalsThe dialogue explores the impact of commercial competition on market share, emphasizing the potential outcomes ranging from significant competitor success to effective intellectual property defense. It highlights the company's strategy in managing its DMD program, aiming for a 10% efficacy benchmark, despite the challenges posed by the phosphorothioate chemistry used. The discussion underscores the importance of early patient treatment, expanding the prescriber base, and the robust life cycle management plan for the company's growth, while noting the slower growth in older patient segments and the focus on international markets.
Setting Ambitious Targets for Dystrophin Levels in Muscular Dystrophy TreatmentThe discussion focuses on establishing a target for dystrophin levels in treating muscular dystrophy, aiming for a 10% steady-state level based on human genetic data, which is expected to significantly improve patient outcomes. The team acknowledges the need for functional data assessment alongside the dystrophin target, viewing it as a critical benchmark for meaningful progress in the field. A clarification is made regarding the 27th figure, emphasizing it as a range of potential outcomes rather than a definitive guidance.
Strategic Considerations in Drug Approval Processes and Asset Enhancement in HealthcareDiscussion revolves around strategic concerns regarding drug approval timelines, emphasizing the importance of one-year data versus full Phase 3 trials for FDA approval. It also explores leveraging under-resourced assets by enhancing patient identification and outreach efforts to optimize healthcare outcomes.
Discussion on Competitor Timelines, Orphan Drug Exclusivity, and Balance Sheet StrategyA discussion covers competitor approval and launch timelines, orphan drug exclusivity for children under 5, potential switching to competitors, and the company's balance sheet capacity and efficient structure. The focus is on leveraging capabilities for rare disease treatments and future indications, with an emphasis on clinical program execution and regulatory interactions.
Patient Therapy Switching, Efficacy Impact, and Corporate Financial FirepowerDiscussion highlights patient adherence to effective treatments, emphasizing the decision-making process involving physicians and families. Corporate financial status is revealed, indicating substantial growth capital availability, crucial for strategic investments.
Orphan Drug Exclusivity and Market Forecasting Amidst Competitive DynamicsDiscussion covers the impact of orphan drug exclusivity on market projections, with emphasis on the company's petition to FDA for Vox Ogo's exclusivity. The dialogue also addresses the revision of financial forecasts considering competitive data and phase 3 trials, highlighting the range of potential outcomes for 2027 revenue, from conservative estimates aligning with current consensus to more optimistic scenarios exceeding $4 billion, influenced by IP defense success and portfolio performance.
Bio Orama's Q3 Results Highlight Strategic Investments, Revenue Guidance, and Cash GrowthThe company reports strong Q3 performance, raising full year revenue guidance and affirming 2025 outlook. Emphasizes strategic investments in enzyme therapies and skeletal conditions, achieving expanded profitability and cash flow growth. Anticipates future data readouts, approvals, and business development opportunities for continued growth.
要点回答
Q：What are the key financial results that led to the revenue guidance update?
A：The key financial results that led to the revenue guidance update include a strong performance across the business resulting in the raising of full year total revenues guidance at the midpoint and reaffirmation of the October revenue outlook for 2025. Notably, top line growth year over year of 11%, expanding profitability, significant growth in operating cash flow, and a cash and investments balance of approximately $2 billion dollars were reported.
Q：What is the rationale behind the decision to divest Rovogt and what is the alternative plan for it?
A：The rationale behind the decision to divest Rovogt is that it did not meet the company's criteria for advancement. The alternative plan for Rovogt is to find an option that will allow it to reach its full potential as an innovative gene therapy within the treatment landscape for severe hemophilia A.
Q：What is the reason for the IPR&D charge in the third quarter?
A：The IPR&D charge in the third quarter is related to the inosine pharma acquisition completed on July 1 of that year. It represents an approximate impact of 1 dollar 10 cents on a per share basis.
Q：How has the tax expense been affected by the IPR&D charge?
A：The tax expense has been affected by the IPR&D charge due to the timing impact of the charge on the quarterly estimated tax rate and some tax benefits from the recently enacted tax law. This resulted in a lower tax expense during the third quarter.
Q：What are the updated financial guidance figures for full year 2025?
A：The updated financial guidance for full year 2025 includes total revenues between $3.15 billion and $3.25 billion, a non GAAP operating margin between 26% and 27%, and non GAAP diluted earnings per share between $3.50 and $3.60.
Q：What is the updated 2027 revenue outlook and what are the challenges in predicting it?
A：The updated 2027 revenue outlook indicates a range from line with current 2027 top line consensus per fax set, excluding roctavian, to scenarios that could reach $4 billion in total 2027 revenues, also excluding roctavian. The challenges in predicting it stem from many unknowns and variables, mostly the impact of Vao go potential competition, and the difficulty in predicting outcomes with enough certainty.
Q：How many countries has the treatment of achondroplasia been available in, and what has driven revenue growth?
A：The treatment of achondroplasia was available in 55 countries as of the end of the third quarter, driving year over year box Sogo revenue growth of 15% in the third quarter and 24% year to date.
Q：What has been done to address the slower uptake in older children in the US?
A：The company has implemented initiatives to address the slowing uptake in older children in the US, which include expanding the prescriber base across the country and increasing the number of children on therapy across all age groups in Q3 versus Q2.
Q：What are the expectations for bmn 333 and the next indications in the skeletal conditions business unit?
A：Bmn 333 represents the next generation product with the potential for greater efficacy and extended dosing intervals. The company plans to start a phase 2 3 study in the first half of 2026, with a focus on more severely impacted subsets of children across the canopy trials and the pursuit of new indications such as hypochondroplasia.
Q：What is the company's strategy for improving early diagnosis of hypochondroplasia?
A：The company is prioritizing improving early diagnosis for hypochondroplasia worldwide through initiatives like genetic reclassification, clinician education, and patient and caregiver awareness. They are also optimizing diagnostic pathways to enable children to potentially access therapy early.
Q：When is the data expected for the next phase of hypochondroplasia, and what is the anticipated launch timeline?
A：Data for the next phase of hypochondroplasia is expected in the first half of 2026, with a potential launch in 2027.
Q：What is the significance of the spinal morphology data for children with achondroplasia?
A：The spinal morphology data for children with achondroplasia, presented at asbmr, demonstrated that children treated with Vao go showed improved curvature of the spine after one year of treatment. This is significant as early intervention is essential to prevent complications, and the findings add to the extensive body of evidence supporting the health benefits of Vao go.
Q：What is the anticipated timeline for the initiation of the phase 2 3 study for bmn 333?
A：The initiation of the phase 2 3 study for bmn 333 is anticipated to occur in the first half of 2026.
Q：What is the goal for bmn 333 in terms of efficacy compared to Vao go?
A：The goal for bmn 333 is to deliver superior efficacy versus Vao go without additional safety signals. The molecule is engineered to safely achieve higher free CNP levels to establish a new standard of care for achondroplasia.
Q：What other pipeline highlights are expected in the coming quarters?
A：Other pipeline highlights include phase 2 data readout for Vao go in hypochondroplasia, initiation of the phase 2 3 study for bmn 333 in achondroplasia, potential approval in 2026 for the Palin Zeke label extension for adolescents age 12 to 17, and phase 3 data for bmn 401 in children age 1 to 12 with NPP 1 deficiency.
Q：What are the scenarios represented by the lower and higher case estimates?
A：The lower case estimate reflects a scenario with two competitors successfully launching and taking significant share by 2027, while the high case reflects a scenario where there's a significant delay in competition, such as successful intellectual property transfer.
Q：How did the company's view on competitive impact evolve over time?
A：The company's view on competitive impact evolved from last year's belief that they could absorb some competitive impact into their original forecasts, to a more cautious outlook due to recent marketplace trends and potential future scenarios.
Q：What were the main factors contributing to the decrease in quarterly sales for Foxo?
A：The decrease in quarterly sales for Foxo was attributed to timing shifts in larger orders, with revenue for the second half of the year being back-weighted to the fourth quarter. Market by market forecasts for Q3 and Q4 were also a factor, with Q3 experiencing more pronounced timing shifts.
Q：What is the company's business development strategy and what assets are they focusing on?
A：The company's business development strategy is focused on early-stage collaborations, with an evolution to also look at phase 3 pre-commercial and commercial assets. They are pursuing several deals and have a number of assets in the works, which are in various stages of site selection and negotiation.
Q：What is the company's forecast for sustainable growth and how does it plan to grow the brand?
A：The company targets a high single-digit sustainable growth rate for enzyme therapies over time with voxel. Brand growth will be driven by deeper patient penetration across all markets and indication expansion opportunities. However, potential competition remains uncertain, and the company will closely monitor these variables.
Q：Has the company considered share buybacks or is the capital being held for business development?
A：The company has not officially taken a position on long-term growth forecasts due to numerous uncertainties, hence they are not providing a long-term growth rate at this time. Regarding capital allocation, while they discuss it with their board, the priority remains on business development, which is seen as the greatest opportunity for driving significant top-line growth.
Q：What specific exposure levels are required to achieve clinical superiority over Voxel Go and drive patient switching?
A：The specific exposure levels for achieving clinical superiority over Voxel Go involve an increase of at least 3x on the AUC from the free CNP levels in the phase 1 PK study. Different dose levels in the ongoing study met this criterion, and the company determined a level of differentiation that is clinically meaningful and has the potential to impact health, wellness, and function measures.
Q：What is the expected 2027 consensus revenue figure excluding roctavian, and what are the other elements of the longer-term targets?
A：The expected 2027 consensus revenue figure, excluding roctavian, is $3.65 billion. The longer-term targets include a non-GAAP operating margin starting at 40% and expanding to the low to mid-40s, with CFO's greater than $1.25 billion starting in 2027. These figures are not top-line dependent and are still expected despite potential challenges.
Q：What should be expected for the 9 mg cohort in the 351 pipeline and the powering for the hypochondroplasia trial?
A：For the 9 mg cohort in the 351 pipeline, it is not specified what to expect, but it will be part of the data analysis. The powering for the hypochondroplasia trial is not detailed in the transcript, but the focus is on efficacy, and a minimum delta on efficacy would be necessary to meet the target product profile.
Q：What is the company's target for operating margin next year and what factors will influence this target?
A：The company's target for operating margin next year is to maintain the 40% goal. Factors influencing this target include the company's focus on driving efficiency through cost and process transformation without compromising value-creating activities. If a trade-off between preserving value-creating activities and achieving the 40% margin occurs, value creation will be prioritized to maximize long-term shareholder value.
Q：What clinical data will be crucial in evaluating the effectiveness of the 351 pipeline?
A：Crucial clinical data for evaluating the effectiveness of the 351 pipeline will include safety data from various cohort groups, results from muscle biopsies, and dystrophin levels. Specifically, the company will look at data from the 6 mg and 9 mg per kilogram cohorts, early data from the 12 mg per kilogram cohort, as well as biopsy results and dystrophin levels.
Q：What is the company's view on the potential growth in patients with hypochondroplasia?
A：The company's view on the potential growth in patients with hypochondroplasia is optimistic, supported by data suggesting a growth rate of up to 1.8 cm per year. This data, combined with a well-powered study, provides confidence in the potential efficacy of their product for this condition.
Q：How will working capital optimization initiatives affect future cash flow and capital deployment?
A：Working capital optimization initiatives across the enterprise are anticipated to improve cash flows and potentially be deployed as growth capital in the future. This is a top priority for the company, indicating that cash balances and sustainable cash flow generation could play a significant role in future capital deployment.
Q：What assumptions underlie the company's revenue estimates and how does competition influence these?
A：The company's revenue estimates are based on assumptions that include potential competition from other companies entering the market with similar products. Lower-case estimates assume that two competitors succeed in entering the market by the end of the relevant timeframe and achieve significant share. Higher-case estimates include a range of outcomes, such as less competition or successful intellectual property defense. These scenarios are designed to illustrate the potential revenue impacts from various outcomes.
Q：What trends are the company observing in patient addition and adherence rates for their products?
A：The company is observing positive trends in patient addition, with an increase in patients starting treatment withvoxal (sovo) worldwide, particularly in the US market for children under 2 years old. Adherence rates remain strong, and there is expansion in the prescriber base, primarily in pediatric endocrinology. While older patient growth rates have slowed, the company is working on initiatives to address this and expects them to take time to show results.
Q：What is the company's strategy for the DMD program and how does it relate to the 10% bar?
A：The company's strategy for the DMD program involves setting an ambitious bar of a 10% dystrophin level as a target, based on the belief that this level could significantly improve functional outcomes for patients. The 10% bar was chosen because it is associated with substantial clinical improvements, similar to those seen in Becker's muscular dystrophy. The company will also consider functional data and will use biopsies at the six-month timeframe to track progress towards this goal.
Q：What is the company's approach to competition regarding the 27th and how does it factor into their guidance?
A：The company's approach to potential competition is cautious and based on certain assumptions communicated in their estimates. They have taken middle-of-the-road assumptions regarding competition and factored these into their lower-case revenue estimates. The company does not intend to comment on competitors' individual timelines but has modeled potential successful launches and their impact on their product's market share. The lower end of their revenue estimate remains the projected growth product over the next two years.
Q：How does the company plan to leverage its capabilities post-approval of a product?
A：The company plans to leverage its capability of finding patients, starting them on therapy, and keeping them on therapy, which has been built over 20 years, to achieve significant things for rare diseases, should the product be approved.
Q：What are the company's plans for an adult indication in ependymal brain tumor deficiency area?
A：The company's plans include preparation for an adult indication in the ependymal brain tumor deficiency area, with the goal to recruit difficult-to-find patients and present data from the pivotal study in the first half of the next year.
Q：What is the company's perspective on patient switching in the context of orphan drug exclusivity?
A：The company believes that patient adherence is influenced by their satisfaction with their current treatment. Most patients who are satisfied with their treatment are likely to remain on therapy, irrespective of orphan drug exclusivity, although some may choose to switch.
Q：What is the estimated firepower available to the company for future investments?
A：The estimated firepower available to the company for future investments is between $4 to $5 billion, with $2 billion of cash and investment on hand, a significant portion of which is available to invest in future growth.
Q：What action has the company taken regarding orphan drug exclusivity for its product?
A：The company has submitted a petition to the FDA concerning the drug exclusivity of Vox Ogo, asserting the timing of the exclusivity and seeking recognition of the incentive for innovation in orphan diseases.
Q：How does the company characterize the lower end of its 2027 scenario and the most bullish scenario?
A：The lower end of the company's 2027 scenario is characterized as conservative, with the possibility of superior efficacy versus competitors like Bridge. In the most bullish scenario, the company models revenue at most $4 billion or lower, considering the full range of potential outcomes including success across the entire portfolio or intellectual property defense.
Q：Why is the company not waiting for the phase 3 data from Bridge before revising its forecasts?
A：The company has modeled a range of scenarios including lower cases based on the changing competitive environment and has decided to share the lower case estimates that include two competitors launching successfully, even before the full phase 3 data from Bridge is available.
